The Venture Codex Logo

The Venture Codex

Gilead Sciences

333 Lakeside Dr, Foster City, CA, 94404, United States

Overview

Research-based biopharmaceutical company developing innovative medicines.

Founded

1987

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series B

Geographic focus

United States

Sector focus

Biopharma
Biotechnology
Health Care
Manufacturing
...

Investment portfolio

20rounds
NAMEDATESIZE
Ensoma
Sep 2025Participated
$53 MOther Equity
Arcus Biosciences
Jan 2024Led
$320 MOther Equity
Hookipa Pharma
Dec 2023Led
$21 MOther Equity
Tentarix Biotherapeutics
Sep 2023Participated
$35 MSeries B
Kyverna Therapeutics
Aug 2023Participated
$60 MSeries B
Exavir Therapeutics
May 2022Participated
$4 MSeed
Curebase
May 2022Participated
$40 MSeries B
Kyverna Therapeutics
Jan 2022Participated
$85 MSeries B
Lyndra Therapeutics
Jun 2021Participated
$61 MSeries C
Barinthus Biotherapeutics
Mar 2021Participated
$168 MSeries B
Tango Therapeutics
Aug 2020Participated
$50 MOther Equity
Glympse Bio
Jul 2020Participated
$47 MSeries B
Ensoma
Sep 2025Participated
$53 MOther Equity
Arcus Biosciences
Jan 2024Led
$320 MOther Equity
Hookipa Pharma
Dec 2023Led
$21 MOther Equity
Tentarix Biotherapeutics
Sep 2023Participated
$35 MSeries B
Kyverna Therapeutics
Aug 2023Participated
$60 MSeries B
Exavir Therapeutics
May 2022Participated
$4 MSeed
Curebase
May 2022Participated
$40 MSeries B
Kyverna Therapeutics
Jan 2022Participated
$85 MSeries B
Lyndra Therapeutics
Jun 2021Participated
$61 MSeries C
Barinthus Biotherapeutics
Mar 2021Participated
$168 MSeries B
Tango Therapeutics
Aug 2020Participated
$50 MOther Equity
Glympse Bio
Jul 2020Participated
$47 MSeries B
20
Items
...
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Gilead Sciences: 20 funding rounds are recorded in the selected participation categories.All available history.
Gilead Sciences: 20 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed01
Series A02
Series B011
Series C+02
Other Equity22

Monthly Deal Activity

Gilead Sciences: 20 deals are recorded across 107 months.All available history.
Gilead Sciences: 20 deals are recorded across 107 months. All available history
MonthDeals
Dec '171
Jan '181
Feb '180
Mar '180
Apr '180
May '180
Jun '181
Jul '180
Aug '180
Sep '180
Oct '181
Nov '180
Dec '180
Jan '191
Feb '190
Mar '190
Apr '190
May '191
Jun '190
Jul '190
Aug '190
Sep '190
Oct '191
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '201
Jul '201
Aug '201
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '211
Apr '210
May '210
Jun '211
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '221
Feb '220
Mar '220
Apr '220
May '222
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '231
Sep '231
Oct '230
Nov '230
Dec '231
Jan '241
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '251
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Gilead Sciences: Health & Life Sciences is the largest displayed sector by deal count (20 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Gilead Sciences: Health & Life Sciences is the largest displayed sector by deal count (20 deals). All available history
SectorDeals
Health & Life Sciences20
Manufacturing2
Space & Frontier Tech2

Deal Size Distribution

Gilead Sciences: 20 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Gilead Sciences: 20 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M1
$5M-$10M0
$10M-$25M2
$25M-$50M3
$50M-$100M8
$100M-$250M5
$250M-$500M1
$500M-$1B0
$1B+0

Deals By Geography

Gilead Sciences: United States has the largest recorded deal count among the displayed regions (19 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Gilead Sciences: United States has the largest recorded deal count among the displayed regions (19 deals). All available history
RegionDeals
United States19
Europe1
Gilead Sciences: 20 co-investors are shown, with Cormorant Asset Management sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Gilead Sciences: 20 co-investors are shown, with Cormorant Asset Management sharing 3 recorded deals. All available history
Co-investorShared deals
Cormorant Asset Management3
Invus3
RTW Investments3
Westlake Village BioPartners3
ARCH Venture Partners2
Be The Match BioTherapies2
Bill & Melinda Gates Foundation2
CAM Capital2
Casdin Capital2
Catalio Capital Management2
CRV2
F-Prime Capital2
GreatPoint Ventures2
HOPU Investments2
Insight Partners2
jVen Capital2
Leerink Partners2
LYFE Capital2
Northpond Ventures2
Polaris Partners2

Investment Strategy

Gilead Sciences: Led accounts for 10% and participating for 90% of round participation.All available history.
Gilead Sciences: Led accounts for 10% and participating for 90% of round participation. All available history
CategoryDeals (count)Share (%)
Led210%
Participating1890%
Gilead Sciences: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
Gilead Sciences: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead2100%
Co-led00%

Team

Ahmed Afifi

Vice President - Region Head Latin America

Brian Peters

Senior Director, Procurement

Daniel O'Day

Chairman & CEO

Gary Tully

Head of Legal Operations

Jacopo Andreose

SVP Intercontinental and Global Patient Solutions

Joel Bercu

Associate Director

Stacey Ma

EVP, Head of Pharmaceutical Development & Manufacturing

Teresa Wang

Director, Investor Relations